The Cabinet Committee on Economic Affairs (CCEA) Thursday cleared Rs. 6,400 crore FDI proposal of global healthcare company GlaxoSmithKline to acquire additional 24.33% stake in its India arm. After the purchase, holding of the promoter group firm - GSK group (which owns GlaxoSmithKline Pharmaceuticals) - in the Indian subsidiary will go up to 75% from the current level of 50.67%.